Drugs / XmAb24306
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05646836 | Mar 2023 → Nov 2026 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05243342 | Apr 2022 → Jul 2024 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04250155 | Mar 2020 → May 2026 | cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb24306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05243342 ↗ |
| Route | Intravenous | “Participants will receive intravenous (IV) XmAb24306.” NCT04250155 ↗ |